Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein
about
Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytesVaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanomaTumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccinesNew perspectives on the role of vitiligo in immune responses to melanomaAlphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunitySelf-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapyAgonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.Human IgG3 with extended half-life does not improve Fc-gamma receptor-mediated cancer antibody therapies in miceImmunologic functions as prognostic indicators in melanomaEvaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide.Metastatic melanomas express inhibitory low affinity fc gamma receptor and escape humoral immunity.Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanomaAutoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other".Autoimmune melanocyte destruction in vitiligo.Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer.Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity.Mouse model for pre-clinical study of human cancer immunotherapy.CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction.Fc receptors are required in passive and active immunity to melanoma.Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironmentVaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.The new vaccines: building viruses that elicit antitumor immunity.Calicum microdomains form within neutrophils at the neutrophil-tumor cell synapse: role in antibody-dependent target cell apoptosisA targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancerFc receptor targeting in the treatment of allergy, autoimmune diseases and cancer.Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapyCombination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompCoupling and uncoupling of tumor immunity and autoimmunity.Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapyRequirement for innate immunity and CD90⁺ NK1.1⁻ lymphocytes to treat established melanoma with chemo-immunotherapy.Heteroclitic immunization induces tumor immunityTumor antigens discovery: perspectives for cancer therapy.Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo.Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules.Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunityMultiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma.Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity.Impact of minimal tumor burden on antibody response to vaccinationImproved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma
P2860
Q24647904-A8D3B4DE-BA72-401D-9E38-F2075359E4C7Q24684238-3128C926-EED1-40A4-A558-70BB80A23AE2Q24804837-CE99F0CA-7C09-4AD8-B568-72964F2F63A5Q26996799-4F6B8E7E-E2E7-4995-A4E3-1BFF621F72D1Q28749317-D341D572-CDB4-432A-B4CC-D01EAF0996A7Q30305530-63BCC512-9706-43B4-939E-1C9CBFE78DC0Q33573450-EDFF6AC8-F441-4ED8-BED6-36A0DBF4A2A6Q33707941-2FB631B5-7FF2-493D-AEA3-E97BFEAC1F1DQ33835011-3F57101E-BC2A-42F3-94F6-0C8E348189EBQ33909760-2ECBD9B7-6A1C-46DB-B41D-8C2669CA4D2AQ34002125-222304B5-E29D-47C0-B207-EA64C923AC8EQ34111789-2C879607-DB83-4AE6-A34D-DCD12F32EFAEQ34276512-99C0B390-BADA-405A-8E2C-83DD32EAB2E5Q34335855-DC4C7CA2-D869-4A9A-98B4-2142CB603697Q34613585-929764E9-E933-4B7B-8C28-3C157C38BB24Q35064131-38E0167A-762D-45A3-B694-A30CFC959EDFQ35146595-A1038518-FE34-4BE8-AC3B-A805FD6C626FQ35181705-74B560CB-223B-452A-AF02-0F84C2CF9D68Q35546950-3B7DCC81-C36A-4524-99C9-34385EE2A80DQ35741270-A2CCAD2F-5172-4EF6-A88F-2542CBB382D7Q35783465-E49C799F-5AAB-4D8B-8E20-3FDD83DEE8BDQ35829136-F30AC62F-8FD0-4BE3-B45B-57803C408E15Q35946203-47700323-6691-497F-BC05-5DEA70C7868BQ36045359-8F5F2745-529E-4BC3-B001-611E71807C34Q36057882-B65C162F-4051-4404-9F8E-8EB8C4C44D3DQ36066311-878B6065-336A-4199-944E-CB4AE96196B7Q36369502-3EB94CC1-CC3B-4496-AF7D-A7D06AB960FBQ36375152-56E0D35C-380E-4A9C-9E81-775FE291797EQ36375693-2FB1C256-AA10-409E-BA5F-52595811E5FCQ36380506-FF62C2EB-38FF-4A39-BEB5-C25FA58F9487Q36401731-0812B338-D17A-4B94-BDF3-4C9A4FC008D4Q36401743-66593E20-A0E6-49EA-848D-6DDF583ED2B2Q36438078-E3ECB856-18E7-4B18-9BA2-780BAC634E72Q36453976-86E66FE0-763B-4315-8725-9F3643C2A703Q36456744-1B0A3047-2006-482F-833A-9E16E8B66EEBQ36459336-7B12A233-E027-414D-9F50-2984717C0570Q36696205-39603003-9C5D-484B-9CD3-F61380CF73E4Q37053497-EAA9F7CF-E710-4ADB-A8F6-846C2F70D814Q37073447-86339B9F-B511-499A-8B69-C86A5DFE2379Q37342888-AFEF7CC9-D4F2-417A-B958-B93270458225
P2860
Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Implicating a role for immune ...... gainst the brown locus protein
@ast
Implicating a role for immune ...... gainst the brown locus protein
@en
type
label
Implicating a role for immune ...... gainst the brown locus protein
@ast
Implicating a role for immune ...... gainst the brown locus protein
@en
prefLabel
Implicating a role for immune ...... gainst the brown locus protein
@ast
Implicating a role for immune ...... gainst the brown locus protein
@en
P2093
P2860
P356
P1476
Implicating a role for immune ...... gainst the brown locus protein
@en
P2093
P2860
P304
P356
10.1084/JEM.182.5.1609
P407
P577
1995-11-01T00:00:00Z